Technical Analysis for INSM - Insmed, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Doji - Bullish? | Reversal | 0.00% | |
| Hammer Candlestick | Bullish | -0.99% | |
| 180 Bullish Setup | Bullish Swing Setup | -0.99% | |
| Pocket Pivot | Bullish Swing Setup | -0.99% | |
| Overbought Stochastic | Strength | -0.99% | |
| Multiple of Ten Bearish | Other | -0.91% | |
| Outside Day | Range Expansion | -0.91% | |
| Wide Bands | Range Expansion | -0.91% | |
| Overbought Stochastic | Strength | -0.91% | |
| Bearish Engulfing | Bearish | -3.83% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 10 hours ago |
| Down 2 % | about 10 hours ago |
| 10 DMA Resistance | about 10 hours ago |
| Fell Below 10 DMA | about 10 hours ago |
| 10 DMA Support | about 10 hours ago |
Get a Trading Assistant
- Earnings date: 08/01/2024
Insmed, Inc. Description
Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing targeted inhalation therapies for patients battling serious lung diseases. Its lead candidate ARIKACE is engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the treatment for two identified patient populations comprising cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). The company's Phase III registrational study of ARIKACE in CF patients in Europe and Canada has completed enrollment; and Phase II clinical trial in NTM patients is under way with clinical results. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Infectious Diseases Cystic Fibrosis Microbiology Bacterial Disease Pseudomonas Tuberculosis Bacteriology Lung Diseases Lung Infection Nontuberculous Mycobacteria Lung Infections Mycobacterium
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 70.65 |
| 52 Week Low | 19.74 |
| Average Volume | 3,878,316 |
| 200-Day Moving Average | 30.82 |
| 50-Day Moving Average | 42.60 |
| 20-Day Moving Average | 63.21 |
| 10-Day Moving Average | 67.04 |
| Average True Range | 3.02 |
| RSI (14) | 73.75 |
| ADX | 63.68 |
| +DI | 35.06 |
| -DI | 10.95 |
| Chandelier Exit (Long, 3 ATRs) | 61.58 |
| Chandelier Exit (Short, 3 ATRs) | 62.76 |
| Upper Bollinger Bands | 72.03 |
| Lower Bollinger Band | 54.38 |
| Percent B (%b) | 0.68 |
| BandWidth | 27.92 |
| MACD Line | 7.24 |
| MACD Signal Line | 8.15 |
| MACD Histogram | -0.9075 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 69.75 | ||||
| Resistance 3 (R3) | 69.70 | 68.53 | 69.18 | ||
| Resistance 2 (R2) | 68.53 | 67.66 | 68.55 | 68.99 | |
| Resistance 1 (R1) | 67.43 | 67.12 | 66.85 | 67.48 | 68.80 |
| Pivot Point | 66.26 | 66.26 | 65.96 | 66.28 | 66.26 |
| Support 1 (S1) | 65.16 | 65.39 | 64.58 | 65.21 | 63.88 |
| Support 2 (S2) | 63.99 | 64.85 | 64.01 | 63.69 | |
| Support 3 (S3) | 62.89 | 63.99 | 63.50 | ||
| Support 4 (S4) | 62.94 |
